Cell and Gene Therapy Catapult’s Annual Review 2021
The past year emphasised the strength and world-leading capabilities of the UK cell and gene therapy industry which experienced significant expansion despite the COVID-19 pandemic.
The Cell and Gene Therapy Catapult has published its 2021 Annual Review, highlighting that the UK has become a place of choice to set up advanced therapy medicinal products (ATMP) activities, with 29% of European ATMP companies operating in the country.
Click here to read the Cell and Gene Therapy Catapult’s Annual Review 2021.